-
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
NCT07060807 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Pittsburgh, York
-
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
NCT06022029 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Pittsburgh
-
A Mixed-Methods Metabolomics Investigation of Lifestyle and Energy Balance During Breast Cancer Survivorship
NCT07655934 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: Female
· Pennsylvania: Philadelphia
-
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
NCT06774963 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Philadelphia, Pittsburgh
-
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
NCT05150691 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Philadelphia, Pittsburgh
-
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
NCT06695845 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Horsham
-
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
NCT06103864 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: York
-
A Registry for People With T-cell Lymphoma
NCT05978141 ·
Phase: Not specified ·
Ages: No age limits stated ·
Sex: All (male and female)
· Pennsylvania: Philadelphia
-
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer
NCT06435429 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Philadelphia
-
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
NCT06790693 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Pittsburgh
-
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
NCT05646862 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Bryn Mawr, Easton, Paoli, West Chester
-
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
NCT04802759 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: Female
· Pennsylvania: Philadelphia, Pittsburgh
-
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
NCT03424005 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Philadelphia, Pittsburgh
-
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
NCT06586957 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Philadelphia, Pittsburgh
-
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
NCT07029399 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Pittsburgh
-
A Study for CTC Expression and cfDNA/RNA Assessment in Metastatic Breast Cancer Patients
NCT06833853 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Pittsburgh
-
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
NCT06369285 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Horsham, Philadelphia, Pittsburgh
-
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
NCT06778863 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Philadelphia
-
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
NCT05774951 ·
Phase: Phase 3 ·
Ages: 18 Years to 130 Years ·
Sex: All (male and female)
· Pennsylvania: Clairton, Philadelphia, Pittsburgh, Reading
-
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
NCT06492616 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Allen, Broomall, Hershey, Meadowbrook
-
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
NCT06926868 ·
Phase: Phase 2, Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Allentown, Philadelphia, Pittsburgh
-
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
NCT07114601 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Pittsburgh
-
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
NCT07213791 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Philadelphia
-
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
NCT06952803 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: Male
· Pennsylvania: Hershey, Lancaster, Pittsburgh
-
A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
NCT05877599 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Pittsburgh
-
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
NCT06395519 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Philadelphia
-
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
NCT06312176 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Philadelphia
-
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
NCT07174336 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Bethlehem, Lancaster, Philadelphia, Willow Grove
-
A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
NCT07020117 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Pittsburgh
-
A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer
NCT05534438 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Allentown
-
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
NCT05503797 ·
Phase: Phase 2 ·
Ages: 8 Years and older ·
Sex: All (male and female)
· Pennsylvania: Philadelphia
-
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
NCT06065748 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Bensalem, Lancaster, Philadelphia, York
-
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
NCT07100106 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Hershey, Philadelphia, Pittsburgh
-
A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer
NCT05683418 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: Female
· Pennsylvania: Philadelphia
-
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
NCT07115043 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Pittsburgh
-
A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer
NCT07310420 ·
Phase: Phase 1 ·
Ages: 18 Years to 55 Years ·
Sex: Female
· Pennsylvania: Bethlehem, Sayre
-
ABemacicliB or Abemaciclib and HydroxYchloroquine to Target Minimal Residual Disease in Breast Cancer
NCT04523857 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Philadelphia
-
Active Surveillance in Older Women With ER+ Breast Cancer
NCT07262138 ·
Phase: Not specified ·
Ages: 70 Years and older ·
Sex: Female
· Pennsylvania: Pittsburgh
-
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
NCT06058377 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Allentown, Beaver, Bethlehem, Bryn Mawr
-
An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Patients With Metastatic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer.
NCT07357597 ·
Phase: Phase 4 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Wynnewood
-
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
NCT06418204 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Allentown, Bethlehem, Chambersburg, Danville
-
Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)
NCT04434040 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Philadelphia
-
Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer
NCT04841148 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Philadelphia
-
Axillary Radiotherapy or Axillary Lymph Node Dissection in Patients With Clinically Node- Positive Breast Cancer Undergoing Upfront Tailored Axillary Surgery
NCT07140172 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Philadelphia
-
B.Brilliant Revelation Comparision Study
NCT07067788 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: Female
· Pennsylvania: Philadelphia
-
BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease
NCT07492641 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: West Reading
-
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
NCT06324357 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Hershey
-
Biennial CEM in Women With a Personal History of Breast Cancer
NCT06105749 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 30 Years to 79 Years ·
Sex: Female
· Pennsylvania: Bethel Park, Cranberry Township, Monroeville, Pittsburgh
-
CEM to Reduce Biopsy Rates for Less Than Highly Suspicious Breast Abnormalities: a Prospective Study
NCT05206331 ·
Phase: Phase 4 ·
Ages: 30 Years and older ·
Sex: Female
· Pennsylvania: Pittsburgh
-
CTNNA1 Familial Expansion Study
NCT05126290 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Philadelphia
-
Circulating Tumor DNA
NCT06923527 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Pittsburgh
-
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
NCT05334069 ·
Phase: Not specified ·
Ages: 40 Years to 75 Years ·
Sex: All (male and female)
· Pennsylvania: Allentown, Bethlehem, Danville, East Stroudsburg
-
Comparison of Breast Cancer Screening With CESM to DBT in Women With Dense Breasts
NCT05625659 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 45 Years to 74 Years ·
Sex: Female
· Pennsylvania: Philadelphia
-
DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment
NCT06075953 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: Female
· Pennsylvania: Bryn Mawr, Paoli, Wynnewood
-
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
NCT04852887 ·
Phase: Phase 3 ·
Ages: 50 Years to 70 Years ·
Sex: All (male and female)
· Pennsylvania: Allentown, Bethlehem, Broomall, Chadds Ford
-
Distance-Based Exercise to Preserve Function and Prevent Disability
NCT07059884 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Butler, Indiana, New Castle, Pittsburgh
-
E-Mindfulness Approaches for Living After Breast Cancer
NCT06748222 ·
Phase: Phase 3 ·
Ages: 18 Years to 50 Years ·
Sex: All (male and female)
· Pennsylvania: Carlisle, Chambersburg, Danville, Dickson City
-
ETHAN - ET for Male BC
NCT05501704 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: Male
· Pennsylvania: Philadelphia, Pittsburgh
-
EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)
NCT06401421 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Harrisburg, Hershey, Pittsburgh, Sayre
-
EXERT-BC Cardio: Cardio or Conditioning Training With Breast Cancer
NCT07739563 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 20 Years to 89 Years ·
Sex: Female
· Pennsylvania: Pittsburgh
-
EXERT-BCH Exercise Regimen to Improve Muscle Mass After Treatment of Breast Cancer
NCT06115486 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 20 Years to 89 Years ·
Sex: Female
· Pennsylvania: Pittsburgh
-
EXploring Inflammation and Social deTerminants Study in Breast Cancer Patients
NCT07478016 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: Female
· Pennsylvania: Philadelphia
-
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
NCT04373564 ·
Phase: Phase 4 ·
Ages: 18 Years to 64 Years ·
Sex: All (male and female)
· Pennsylvania: Hershey, Philadelphia
-
Engaging M-health for Symptom Monitoring and Health Promotion for Women on Endocrine Therapy for Breast Cancer (EmSHAPE)
NCT07454499 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: Female
· Pennsylvania: Philadelphia
-
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
NCT05879926 ·
Phase: Phase 3 ·
Ages: 18 Years to 60 Years ·
Sex: Female
· Pennsylvania: Allentown, Bethlehem, Bryn Mawr, Carlisle
-
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
NCT05696626 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Pittsburgh
-
Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer
NCT05455619 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Hershey
-
FES BPET-DBT in Newly Diagnosed Breast Cancer
NCT05659797 ·
Phase: Early Phase 1 ·
Ages: 18 Years and older ·
Sex: Female
· Pennsylvania: Philadelphia
-
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
NCT07216105 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Philadelphia
-
Gene Therapy for HER-Positive Cancer (SENTRY-HER2)
NCT07192432 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Philadelphia
-
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
NCT01042379 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Philadelphia, Pittsburgh
-
Identification of Breast Cancer in Breath Samples Using Trained Detection Dogs
NCT07038785 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: Female
· Pennsylvania: Philadelphia
-
Identifying Patterns in the Breath of Individuals With Breast Cancer
NCT06512350 ·
Phase: Not specified ·
Ages: 40 Years to 74 Years ·
Sex: Female
· Pennsylvania: Pittsburgh
-
Improving Survival for Metastatic Lobular Breast Cancer (PLUMB Registry)
NCT05964504 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Philadelphia
-
Increasing Germline Genetic Testing for Patients With Cancer
NCT07307664 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: No age limits stated ·
Sex: All (male and female)
· Pennsylvania: Danville
-
Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease
NCT03808337 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Allentown
-
Long-term Safety of Nipple Sparing Mastectomy in Women With High Penetrance Breast Cancer Susceptibility Genes in Breast Cancer
NCT06888388 ·
Phase: Not specified ·
Ages: 18 Years to 90 Years ·
Sex: Female
· Pennsylvania: Philadelphia
-
Longitudinal Tumor Burden Quantification Using Circulating Tumor DNA in Metastatic Lobular Breast Cancer
NCT06666439 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: Female
· Pennsylvania: Pittsburgh
-
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
NCT03053193 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Bethlehem, Broomall, Horsham, Langhorne
-
Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy
NCT02945579 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 30 Years and older ·
Sex: Female
· Pennsylvania: Pittsburgh
-
Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers
NCT05919108 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Pittsburgh
-
PENN-Surveillance Markers of Utility for Recurrence After (Neo)Adjuvant Therapy for Breast Cancer
NCT02732171 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Philadelphia
-
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
NCT07085767 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Horsham, Sayre
-
Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab
NCT06249048 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Pittsburgh
-
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
NCT06757634 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Philadelphia
-
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
NCT05232916 ·
Phase: Phase 3 ·
Ages: 18 Years to 100 Years ·
Sex: All (male and female)
· Pennsylvania: Meadowbrook, Philadelphia
-
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
NCT05827081 ·
Phase: Phase 3 ·
Ages: 18 Years to 100 Years ·
Sex: All (male and female)
· Pennsylvania: Drexel Hill, Harrisburg, Pittsburgh
-
Pre-operative SABR With and Without Caloric Restriction for Early Stage Breast Cancer
NCT04959474 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 40 Years and older ·
Sex: All (male and female)
· Pennsylvania: Philadelphia
-
Prospective Breast Cancer Biospecimen Collection
NCT04074720 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Philadelphia
-
Prospective Study of EXErcise Regimens After Treatment for Breast Cancer for Hypertrophy and Conditioning
NCT07023887 ·
Phase: Not specified ·
Ages: 20 Years to 89 Years ·
Sex: Female
· Pennsylvania: Pittsburgh
-
Proteomics and Radiomics Research of Breast Cancer Markers in Tissue, Interstitial Fluid and Serum
NCT01042548 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Pittsburgh
-
QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer
NCT06551116 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Philadelphia, Pittsburgh
-
Resistance Training and Post Workout Protein to Improve Body Composition During Neoadjuvant Chemotherapy for Breast Cancer
NCT06858449 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 20 Years to 89 Years ·
Sex: Female
· Pennsylvania: Pittsburgh
-
Responses to Genetic Risk Modifier Testing Among Women With Pathogenic Variants in Breast Cancer Predisposition Genes
NCT03396341 ·
Phase: Not specified ·
Ages: 25 Years and older ·
Sex: Female
· Pennsylvania: Philadelphia
-
Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer
NCT05467891 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Hershey
-
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
NCT05579366 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Doylestown, Pittsburgh
-
Role of the Immune Environment in Response to Therapy in Breast Cancer
NCT05396612 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: Female
· Pennsylvania: Philadelphia
-
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
NCT03418961 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Allentown, Bethlehem, Bryn Mawr, Chadds Ford
-
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
NCT03723928 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Pennsylvania: Allentown, Bethlehem, Danville, Doylestown
-
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
NCT03452774 ·
Phase: Not specified ·
Ages: No age limits stated ·
Sex: All (male and female)
· Pennsylvania: Philadelphia